{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T06:16:28Z","timestamp":1778220988747,"version":"3.51.4"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Filaggrin (FLG) plays an important role in the progression of malignant tumors; however, its expression characteristics and biological functions in gastric cancer (GC) remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Cancer-related datasets were retrieved from public repositories, including the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA). A competing endogenous RNA (ceRNA) network was constructed to explore potential regulatory networks involving FLG. Differential expression analysis, genetic alteration analysis, and clinicopathological and survival analyses were performed to evaluate the role of FLG in GC. In addition, Gene Set Enrichment Analysis (GSEA), immune infiltration analysis, and in vitro functional experiments were conducted to investigate the biological effects and potential mechanisms of FLG in GC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>FLG was aberrantly expressed across multiple cancer types and was significantly associated with clinical characteristics and prognosis in GC. Further analyses showed that FLG was involved in genetic alterations and was closely associated with the immune microenvironment in GC. Functional experiments demonstrated that FLG promoted the invasion and metastasis of GC cells. Mechanistically, GSEA and experimental validation indicated that FLG exerted its tumor-promoting effects, at least in part, through activation of the epithelial-mesenchymal transition (EMT) signaling pathway.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study clarifies the biological role of FLG in GC and highlights its potential as a novel prognostic biomarker and therapeutic target. These findings provide new insights into the molecular mechanisms underlying GC progression and may contribute to the development of more effective diagnostic and therapeutic strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1742982","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:55:04Z","timestamp":1778219704000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Filaggrin as a potential biomarker in gastric cancer: insights from multi-omics analysis and experimental validation"],"prefix":"10.3389","volume":"17","author":[{"given":"Nan","family":"Xia","sequence":"first","affiliation":[{"name":"National Clinical Research Center for Medical Auxiliary Technology (Laboratory Medicine), Department of Laboratory Medicine, The First Hospital of China Medical University","place":["Shenyang, Liaoning, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianru","family":"Ben","sequence":"additional","affiliation":[{"name":"The First Clinical College of China Medical University","place":["Shenyang, Liaoning, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Guan","sequence":"additional","affiliation":[{"name":"The First Clinical College of China Medical University","place":["Shenyang, Liaoning, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linlin","family":"Gao","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Medical Auxiliary Technology (Laboratory Medicine), Department of Laboratory Medicine, The First Hospital of China Medical University","place":["Shenyang, Liaoning, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Yuan","sequence":"additional","affiliation":[{"name":"Tumor Etiology and Screening Department of Cancer Institute and General Surgery, Key Laboratory of Cancer Etiology and Prevention, The First Hospital of China Medical University, China Medical University","place":["Shenyang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33587","article-title":"The ever increasing importance of cancer as a leading cause of premature death worldwide","volume":"127","author":"Bray","year":"2021","journal-title":"Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30073-5","article-title":"Cancer registration in China and its role in cancer prevention and control","volume":"21","author":"Wei","year":"2020","journal-title":"Lancet Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00347-z","article-title":"Systemic immunity in cancer","volume":"21","author":"Hiam-Galvez","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/0923-1811(93)90837-f","article-title":"Characterization of the human epidermal profilaggrin gene. Genomic organization and identification of an S-100-like calcium binding domain at the amino terminus","volume":"267","author":"Presland","year":"1992","journal-title":"J Biol Chem"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/ng2020","article-title":"Comprehensive analysis of the gene encoding filaggrin uncovers prevalent and rare mutations in ichthyosisvulgaris and atopic eczema","volume":"39","author":"Sandilands","year":"2007","journal-title":"Nat Genet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-019-01956-3","article-title":"Loss of function mutations in the gene encoding filaggrin cause ichthyosisvulgaris","volume":"38","author":"Smith","year":"2006","journal-title":"Nat Genet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.08.067","article-title":"Toward a major risk factor for atopic eczema: meta-analysis of filaggrin polymorphism data","volume":"120","author":"Baurecht","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/cod.12097","article-title":"Carriers of filaggrin gene (FLG) mutations avoid professional exposure to irritants in adulthood","volume":"69","author":"Bandier","year":"2013","journal-title":"Contact Dermatitis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/ng1743","article-title":"Filaggrin lossof-function mutations and incident cancer: a populationbased study","volume":"171","author":"Skaaby","year":"2014","journal-title":"Br J Dermatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2332\/allergolint.10-rai-0270","article-title":"Filaggrin gene defects and the risk of developing allergic disorders","volume":"60","author":"Osawa","year":"2011","journal-title":"Allergol Int"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32775","article-title":"High-risk stage III colon cancer patients identified by a novel five-gene mutational signature are characterized by upregulation of IL-23A and gut bacterial translocation of the tumor microenvironment","volume":"146","author":"Ge","year":"2020","journal-title":"Int J Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2174\/0118761429318398240918063450","article-title":"Upregulation of LncRNA WT1-AS inhibits tumor growth and promotes autophagy in gastric cancer via suppression of PI3K\/Akt\/mTOR pathway","volume":"17","author":"Zhang","year":"2024","journal-title":"Curr Mol Pharmacol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2174\/0118761429322420241112051105","article-title":"Exploring the pharmacological mechanisms of P-hydroxylcinnamaldehyde for treating gastric cancer: a pharmacological perspective with experimental confirmation","volume":"17","author":"Fatima","year":"2024","journal-title":"Curr Mol Pharmacol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"194","DOI":"10.21203\/rs.3.rs-4286067\/v1","article-title":"Anti-cancer bioactive peptide induces apoptosis in gastric cancer cells through TP53 signaling cascade","volume":"32","author":"Suyila","year":"2025","journal-title":"Protein Pept Lett"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2174\/0115665232247694230921060213","article-title":"A retrospective analysis of the Lauren classification in the choice of XELOX or SOX as an adjuvant chemotherapy for gastric cancer","volume":"24","author":"Wang","year":"2024","journal-title":"Curr Gene Ther"},{"key":"B18","doi-asserted-by":"publisher","first-page":"E2089","DOI":"10.3390\/cancers12082089","article-title":"Comprehensive cohort analysis of mutational spectrum in early onset breast cancer patients","volume":"12","author":"Midha","year":"2020","journal-title":"Cancers"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-14-0077","article-title":"Skin barrier dysfunction and low antimicrobial peptide expression in cutaneous T-cell lymphoma","volume":"20","author":"Suga","year":"2014","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"E862","DOI":"10.3390\/nu12030862","article-title":"Expression profiles of genes encoding cornified envelope proteins in atopic dermatitis and cutaneous T-cell lymphomas","volume":"12","author":"Trzeciak","year":"2020","journal-title":"Nutrients"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-019-01956-3","article-title":"Filaggrin sequencing and bioinformatics tools","volume":"312","author":"Margolis","year":"2020","journal-title":"Arch Dermatol Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.808542","article-title":"Association of FLG mutation with tumor mutation load and clinical outcomes in patients with gastric cancer","volume":"13","author":"Yicheng","year":"2022","journal-title":"Front Genet"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/bf00931354","article-title":"Altered expression of filaggrin in human papillomavirus (HPV) lesions of the uterine cervix","volume":"241","author":"Cintorino","year":"1988","journal-title":"Arch Gynecology Obstet"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/bf02391801","article-title":"Immunohistochemical localization of filaggrin in benign, premalignant and Malignant cervical tissue","volume":"255","author":"Lara","year":"1994","journal-title":"Arch Gynecology Obstet"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.15822","article-title":"Screening and identification of potential prognostic biomarkers in metastatic skin cutaneous melanoma by bioinformatics analysis","volume":"24","author":"Sheng","year":"2020","journal-title":"J Cell Mol Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2016.1240857","article-title":"Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk","volume":"5","author":"Salerno","year":"2016","journal-title":"Oncoimmunology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0905139106","article-title":"Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival","volume":"106","author":"Bogunovic","year":"2009","journal-title":"PNAS"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-11-3218","article-title":"Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma","volume":"72","author":"Erdag","year":"2012","journal-title":"Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/sla.0000000000003522","article-title":"The barrier molecules junction plakoglobin, filaggrin, and dystonin play roles in melanoma growth and angiogenesis","volume":"270","author":"Leick","year":"2019","journal-title":"Ann Surg"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2019-206400","article-title":"Integrated characterisation of cancer genes identifies key molecular biomarkers in stomach adenocarcinoma","volume":"73","author":"Wang","year":"2020","journal-title":"J Clin Pathol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-310814","article-title":"Interaction between tumour-infiltrating b cells and T cells controls the progression of hepatocellular carcinoma","volume":"66","author":"Garnelo","year":"2017","journal-title":"Gut"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0061-z","article-title":"Natural killer cells and other innate lymphoid cells in cancer","volume":"18","author":"Chiossone","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-022-00491-0","article-title":"Natural killer cells in antitumour adoptive cell immunotherapy","volume":"22","author":"Laskowski","year":"2022","journal-title":"Nat Rev Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1742982\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:55:05Z","timestamp":1778219705000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1742982\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":33,"alternative-id":["10.3389\/fimmu.2026.1742982"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1742982","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"article-number":"1742982"}}